Jeffrey Bacha

It was an honor to present an update on @DelMarPharma's ongoing clinical trials of VAL-083 at #AACR18 with my Co-Founder and Chief Scientific Officer Dr. Dennis Brown. $DMPI

.@rosadelauro It was a pleasure meeting you. Thank you for taking the time to speak with the DelMar team & for all of your work with the bipartisan Congressional #OvarianCancer Caucus

Thank you @OCRFA for speaking with DelMar during our visit to Washington D.C. Learn about their work in the fight against #OvarianCancer bit.ly/2Aj7BR3

Thank you to @RepAnnaEshoo & her staff for taking the time to speak with the DelMar team & for your dedication in the fight against #cancer

Thank you to @theNCI researchers for meeting with the DelMar team today ahead of the @NBTSTweets Research Roundtable.

.@JeffreyBacha, co-founder & CEO of @DelMarPharma, will discuss DelMar innovations at #BT5KTwinCities. Join us tmrw! hope.abta.org/twincities2017

Thank you @wallstanalyzer for having me to discuss $DMPI's four clinical trials of our lead product VAL-083 bit.ly/2xateRf

Thank you @upticknewswire for having me to discuss DelMar & our development programs of our lead product VAL-083 bit.ly/2xIn2nz

Addressing MGMT-unmethylated GBM represents one of the largest unmet needs in the treatment of #cancer today bit.ly/2w0EdB1

Goal of our Ph 2 study to establish VAL-083 + radiation as alternative to TMZ + radiation for MGMT-unmethylated GBM bit.ly/2w0EdB1

Our new Ph 2 trial leverages historical data demonstrating promising activity of VAL-083 in newly diagnosed #GBM bit.ly/2w0EdB1

Listen to my Rodman & Renshaw presentation today at 12:05PM ET where I'll discuss our pivotal STAR-3 trial bit.ly/1X38sej $DMPI

DelMar CEO Jeffrey Bacha and GBM patient Rob Thomson at the Finish Line of The British Columbia Ride to Conquer Cancer.

It was an honor riding with @BrainiacsCT in @TheBCRide, thank you to everyone for your donations & support!

Valuable lessons can be learned from first-hand experiences, concerns, thoughts & feelings expressed by GBM patients bit.ly/2v5CntC

Read my new blog "Patients, the Center of our Efforts" via @SeekingAlpha bit.ly/2v5CntC $DMPI

We are excited to be advancing VAL-083 into newly diagnosed GBM bit.ly/2uPN7QD

VAL-083 represents a potential paradigm shift in the treatment of #GBM bit.ly/2uPN7QD $DMPI

Activation of STAR-3 trial & initiation of recruitment @ @DentInstitute is a momentous occasion for patients & $DMPI bit.ly/2vft4bv

We're excited for completion of 1st site initiation visit for STAR-3 pivotal Ph3 trial of VAL-083 in refractory #GBM bit.ly/2vft4bv